real-time news and commentary for investors
Friday, May 24
The California Institute for Regenerative Medicine grants Sangamo BioSciences (SGMO) a $6.4M...
The California Institute for Regenerative Medicine grants Sangamo BioSciences (SGMO) a $6.4M award to develop its ZFP-genome editing technology for the treatment of beta-thalassemia with the ultimate goal of eliminating the need for chronic blood transfusions in patients. SGMO says "the four year grant provides matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial." A recent article by SA contributor Life Sciences Report favorably mentions companies (like SGMO) with platform technologies. (PR)